Estate Counselors’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-4,590
Closed -$1.18M 121
2023
Q3
$1.18M Buy
4,590
+35
+0.8% +$9.36K 0.16% 86
2023
Q2
$1.3M Hold
4,555
0.16% 86
2023
Q1
$1.27M Buy
+4,555
New +$1.26M 0.17% 73
2021
Q4
Sell
-3,795
Closed -$1.07M 168
2021
Q3
$1.07M Buy
3,795
+30
+0.8% +$9.83K 0.13% 95
2021
Q2
$1.3M Buy
3,765
+80
+2% +$24.2K 0.17% 67
2021
Q1
$1.03M Buy
3,685
+420
+13% +$113K 0.15% 89
2020
Q4
$799K Buy
3,265
+1,635
+100% +$422K 0.12% 87
2020
Q3
$462K Buy
1,630
+40
+3% +$11.2K 0.07% 97
2020
Q2
$425K Buy
1,590
+50
+3% +$15K 0.07% 103
2020
Q1
$487K Buy
+1,540
New +$467K 0.08% 78

Other funds holding BIIB

Estate Counselors's BIIB Position: Q4 2023 in Review

Estate Counselors sold out of Biogen (BIIB) in Q4 2023, closing a stake of 4,590 shares — an estimated $1.18M sold.

Estate Counselors first reported a position in BIIB in Q1 2020 and held it in 10 quarters. The position peaked at $1.3M in Q2 2021. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q4 2023.

  • Estate Counselors reported no remaining Biogen position as of Q4 2023 after selling out during the quarter.
  • Estate Counselors sold 4,590 Biogen shares in Q4 2023, an estimated $1.18M.
  • Estate Counselors first reported a position in Biogen in Q1 2020 and held it in 10 quarters.
  • Estate Counselors's Biogen position peaked at $1.3M in Q2 2021.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q4 2023.

Based on Estate Counselors's 13F filing for Q4 2023, filed 23 Jan 2024.